Cervical cancer is the third most common gynecologic cancer in the United States. Two proven approaches to cervical cancer prevention: conventional cytology screening and human papillomavirus (HPV) vaccination.
Prevention guidelines recommend screening every one to three years after onset of sexual activity. Many states have passed legislation to require mandatory HPV vaccination for school children.
To compare the cost-effectiveness of HPV vaccination combined with conventional cytology screening versus HPV vaccination alone on cervical cancer prevention in the U.S.
Background Objective

Methods
• Study population: Women in the U.S.
• Time horizon: Lifetime Table 3 . Cost-effectiveness analyses of vaccination and screening versus vaccination only for cervical cancer prevention The incremental cost-effectiveness ratio (ICER) for HPV vaccination combined with the triennial screening compared to vaccination alone was $251,812 per QALY gained (Table 3) .
When increasing the frequency of screening to biennial and annual, the ICER of HPV vaccination combined with screening compared to vaccination alone changed to $335,505 and $593,195 per QALY gained respectively (Table 3) .
